Skip to main content
padlock icon - secure page this page is secure

RelA suppresses the Wnt/β-catenin pathway without exerting trans-acting transcriptional ability

Buy Article:

$42.00 + tax (Refund Policy)

Several cellular signaling systems exhibit cross talk. Cross talk seems to play an important role in modifying signal effects. In vertebrates, the nuclear factor κ B (NF-κB) signaling pathway plays important roles in immune response, inflammation and apoptosis. Meanwhile, the Wnt/β-catenin signaling pathway is involved in oncogenesis and development. We show here that RelA, a component of NF-κB, specifically suppressed β-catenin/Tcf-dependent transcription. This suppression did not depend on the trans-acting transcriptional ability of RelA. Furthermore, RelA neither affected the nuclear import of β-catenin nor the DNA binding ability of the β-catenin/Tcf complex, suggesting that NF-κB modifies this signaling pathway after the binding of the β-catenin/Tcf complex with target DNA.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department of Viral Oncology, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan

Publication date: January 1, 2002

More about this publication?
  • The International Journal of Molecular Medicine is a monthly, peer-reviewed journal devoted to the publication of high quality studies related to the molecular mechanisms of human disease. The journal welcomes research on all aspects of molecular and clinical research, ranging from biochemistry to immunology, pathology, genetics, human genomics, microbiology, molecular pathogenesis, molecular cardiology, molecular surgery and molecular psychology.

    The International Journal of Molecular Medicine aims to provide an insight for researchers within the community in regard to developing molecular tools and identifying molecular targets for the diagnosis and treatment of a diverse number of human diseases.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more